 PHASE II TRIAL OF A CHEMOTHERAPY ALONE REGIMEN OF IV BUSULFAN BUSULFEX, MELPHALAN AND FLUDARABINE AS MYELOABLATIVE REGIMEN FOLLOWED BY AN ALLOGENEIC T-CELL DEPLETED HEMATOPOIETIC STEM CELL TRANSPLANT FROM AN HLA-IDENTICAL, OR HLA-NON IDENTICAL RELATED OR UNRELATED DONOR: 